GnuBIO to Present at 14th Annual Rodman & Renshaw Global Investment Conference

Cambridge, MA (September 11, 2012): GnuBIO Inc., a pioneer in the desktop DNA sequencing market, announced that John Boyce, president and chief executive officer, will be presenting at the Rodman & Renshaw 14th Annual Global Investment Conference in New York, NY today on September 11, 2012.

 click to download the PDF of the article

At the conference, Mr. Boyce will provide an update on the company’s activities, including the preparation of its commercialization plans for the launch of its first product, a system that will simplify a complex process by incorporating all the steps required for DNA sequencing into a single platform, including target selection and enrichment, DNA amplification, DNA sequencing and analysis.

Mr. Boyce will be available for one-on-one meetings by contacting register@rodm.com.

For more information on the Rodman & Renshaw Annual Global Investment Conference, including a full program schedule, please visit http://www.rodmanandrenshaw.com/conferences.

About GnuBIO: GnuBIO, is a privately-held company developing next-generation desktop DNA sequencing technology that will compartmentalize the entire DNA sequencing process, combining all of the steps required for sequencing in a single system, and providing the only fully integrated next-generation sequencing workflow. The GnuBIO sequencing technology is based on an emulsion based microfluidic technology which also provides a scalable sequencing solution that allows for interrogation of single genes, gene panels or whole genomes. The user of his GnuBIO system simply injects the patient sample into the GnuBIO cartridge, the appropriate panel is run – inclusive of gene capture, PCR, sequencing, and informatics analysis – and the results are ready within hours. Unlike any other DNA sequencing system, the entire process is all on the chip – the user simply injects genomic DNA, simplifying the complex sample preparation process and breaking the barrier of a an obstacle that has prevented the widespread adoption of DNA sequencing.

For further information on GnuBIO, please contact Susie Harborth, Senior Vice President of Business Operations, at sharborth@gnubio.com.